Srikanth Ranganathan, Ph.D.

Job Title
Program Director
Srikanth Ranganathan
Division of Neuroscience
Cluster, Section, or Program
Neurodegeneration, Dementia, and Repeat Expansion Disorders
Areas of Interest

Portfolio: Spinocerebellar Ataxias (SCAs), Friedreich’s Ataxia (FRDA/FA), Spinal and Bulbar Muscular Atrophy (SBMA), Hereditary Spastic Paraplegias (HSPs); Cell death mechanisms relevant to neurodegenerative disorders and not due to ischemia per se; Basic Mechanisms of Neurodegeneration including Mitochondrial / ER / Calcium homeostasis, RNA biology and protein turnover; Neuromuscular Junction Biology (vertebrate)    

Additional Keywords: Ataxins, spastins, frataxin, and androgen receptors; Purkinje cells, cortical projection neurons, motor neurons, and skeletal muscles; basic mechanisms of neurodegeneration (axonal biology; bioenergetics; metabolism; oxidative and ER stress; autophagy; DNA repair; RNA biology)

Contact Number

Dr. Ranganathan is a Program Director in the Division of Neurodegeneration, Dementia, and Repeat Expansion Disorders (NDR) Cluster at the National Institute of Neurological Disorders and Stroke. He transitioned to NINDS from the Center for Scientific Review (CSR) where he served as an Scientific Review Officer (SRO) and Referral Officer at the Center for Scientific Review in NIH. In this role, Dr. Ranganathan managed the peer-review for the NIH Director's New Innovator Award (DP2) of the trans-NIH Common Fund high risk, high reward program before taking over the chartered study section of Musculoskeletal Tissue Engineering. In addition to the primary role as an SRO, he served as a Referral Officer for the Division of Receipt and Referral at CSR referring applications to the appropriate review branches. Dr. Ranganathan earned a Ph.D. in Cellular and Molecular Pathology (Neuropathology) from the University of Pittsburgh for investigating the molecular mechanisms of ALS and identifying mass spectrometry-based proteomic biomarkers, the latter resulting in an active patent as well as a biotech start-up. Following this, he completed couple of post-doctoral fellowships, the first of which was in the Neurogenetics Branch of NINDS working on polyglutamine diseases (primarily mitochondrial dysfunction in SBMA) followed by a second fellowship on movement disorders (Huntington's and Parkinson's diseases) at the Wallenberg Neuroscience Center, Lund University, Sweden. After successful completion of the fellowships, Dr. Ranganathan served as a Chief Scientific Advisor and consultant in the biotech sector in Lund, Sweden before transitioning to CSR, NIH.

Dr. Ranganathan manages a portfolio of grants in basic mechanisms in neurodegeneration including that of Spinal and Bulbar Muscular Atrophy (SBMA), Hereditary Spastic Paraplegia, Spinocerebellar Ataxias (SCAs), and Friedreich's Ataxia.